Cases of AEF, including death associated with the use of percutaneous RF ablation catheters for the treatment of AF, have been reported in Canada and internationally.
Products affected
|
Manufacturer/Canadian distributor |
Device Name |
CF-sensing |
|
Biotronik |
ALCATH/ALCATH FLUX MAPPING AND ABLATION CATHETERS |
No |
|
Boston Scientific |
STINGER ABLATION CATHETER |
No |
|
CHILL II COOLED ABLATION CATHETER |
No |
|
BLAZER OPEN-IRRIGATED ABLATION CATHETER |
No |
|
INTELLATIP MIFI OPEN-IRRIGATED ABLATION CATHETER |
No |
|
INTELLANAV OPEN-IRRIGATED ABLATION CATHETER |
No |
|
BLAZER CARDIAC ABLATION CATHETERS |
No |
|
BLAZER PRIME XP TEMPERATURE ABLATION CATHETERS |
No |
|
INTELLANAV TEMPERATURE ABLATION CATHETERS |
No |
|
Johnson & Johnson Medical Products |
THERMOCOOL SMARTTOUCH DIAGNOSTIC/ABLATION DEFLECTABLE TIP CATHETER |
Yes |
|
NAVI-STAR DIAGNOSTIC/ ABLATION DEFLECTABLE TIP CATHETER |
No |
|
NON-NAVIGATIONAL CATHETERS |
No |
|
NAVIGATIONAL BI-DIRECTIONAL CATHETERS |
No |
|
RMT DIAGNOSTIC/ABLATION STEERABLE TIP CATHETER |
No |
|
DIAGNOSTIC/ ABLATION ELECTROPHYSIOLOGY CATHETERS |
No |
|
CELSIUS RMT DIAGNOSTIC/ ABLATION STEERABLE TIP CATHETER |
No |
|
Abbott Laboratories |
TACTICATH QUARTZ |
Yes |
|
SAFIRE BIDIRECTIONAL ABLATION CATHETER |
No |
|
FLEXABILITY ABLATION CATHETER, SENSOR ENABLED |
No |
|
LIVEWIRE TC(TM) ABLATION CATHETERS |
No |
|
THERAPY COOL PATH ABLATION CATHETER |
No |
|
SAFIRE DUO ABLATION CATHETER MEDIGUIDE ENABLED |
No |
|
COOLPATH DUO ABLATION CATHETER MEDIGUIDE ENABLED |
No |
|
SAFIRE BLU |
No |
|
THERAPY ABLATION CATHETERS |
No |
|
FLEXABILITY ABLATION CATHETER |
No |
|
THERAPY COOL FLEX |
No |
|
Medtronic |
PULMONARY VEIN ABLATION CATHETER GOLD |
No |
|
RF ENHANCR II STEERABLE ELECTRODE CATHETER FOR INTRACARDIAC ABLATION |
No |
|
RF MARINR STEERABLE ELECTRODE CATHETER FOR INTRACARDIAC ABLATION |
No |
|
RF CONTACTR STEERABLE ELECTRODE CATHETER FOR INTRACARDIAC ABLATION |
No |
Background information
The percutaneous ablation catheters are single use devices used for the treatment of symptomatic arrhythmia, most commonly AF, which do not respond to drug therapies. They are designed to facilitate electrophysiological mapping, pacing (some brands) of the heart chambers, and when used in conjunction with a compatible RF generator, to transmit RF energy to the cardiac tissues in order to block the erratic electrical signals.
When RF ablation catheters are used to treat AF, an AEF may develop as a result of esophageal injury due to the close anatomic relationship between the esophagus and the heart. A diagnosis of AEF may not be considered in a timely fashion due to delayed and non-specific clinical presentation potentially occurring in the majority of cases. The risk is low, but AEF is associated with high mortality, reported as being between 67% and 100% of cases.
1 Clinical observations of delayed onset of AEF support theories of either a direct thermal injury to the esophagus, or heat damage to the anterior esophageal arteries, causing ischemia, ulceration and fistulisation.
1,2 Predictors of AEF may include anatomical factors such as an enlarged left atrium occasionally seen in patients with persistent AF and the shorter distance between the heart and the digestive tract seen in patients with a low body weight, a history of gastroesophageal reflux, higher RF power setting, and potential injury to the esophagus related to general anesthesia and the use of a nasogastric tube during anesthesia.
Health Canada is aware of rare Canadian and international cases of AEF resulting from the use of percutaneous RF catheters for AF ablation.
3,4,5,6 Among the four Canadian cases of AEF that were reported to Health Canada, the complication was identified at any time between days and weeks following the RF ablation procedures. Health Canada’s assessment of these four cases concluded a strong causal link between the use of the catheter and the AEF in two cases, and a possible causal link in the remaining two cases. Three of these four cases resulted in a fatal outcome and cause of death was probably due to the catheter use in only one case. Another four Canadian reports of AEF including three fatalities were found in the published literature. However, given the lack of sufficient information, causal link for these cases was not assessed by Health Canada.
Several preventative measures have been suggested in the literature. These may include determining the location of the esophagus and avoiding making a lesion near it, reduction of RF power and shortening application time and mechanical displacement of the esophagus.
7 Each of these preventative measures has advantages and disadvantages and clinical evidence does not appear to be always consistent. Clinical studies have shown that despite preventative measures taken during the procedure, esophageal thermal injuries may still happen.
6,8 Health Canada recognizes that AEF may occur following AF ablation with other technologies including cryoablation or high-intensity focused ultrasound.